Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Epoxide Hydrolase
    (18)
  • COX
    (1)
  • FAAH
    (1)
  • FLAP
    (1)
  • IL Receptor
    (1)
  • PPAR
    (1)
  • Prostaglandin Receptor
    (1)
  • TNF
    (1)
  • Others
    (28)
Filter
Search Result
Results for "

soluble epoxide hydrolase

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    52
    TargetMol | Inhibitors_Agonists
  • Dye Reagents
    1
    TargetMol | Dye_Reagents
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    4
    TargetMol | Natural_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
Soluble epoxide hydrolase inhibitor
T129741241826-88-9
Soluble epoxide hydrolase inhibitor is a soluble epoxide hydrolase inhibitor (human soluble epoxide hydrolase (h-sEH) with pIC50 of 8.4).
  • Inquiry Price
6-8 weeks
Size
QTY
Soluble Epoxide Hydrolase PROTAC 1a
sEH Proteolysis-targeting Chimera 1a,Soluble Epoxide Hydrolase Proteolysis-targeting Chimera 1a,sEH PROTAC 1a
T83857
Soluble epoxide hydrolase (sEH) PROTAC 1a is a proteolysis-targeting chimera (PROTAC) comprising a cereblon ligand linked to the sEH inhibitor t-TUCB via a linker, promoting selective sEH degradation and inhibiting its hydrolase activity (IC50 = 0.8 nM) significantly more than its phosphatase activity (IC50 = >10,000 nM). This compound preferentially targets cytosolic sEH for lysosomal rather than proteasomal degradation. Furthermore, it mitigates thapsigargin-induced upregulation of phosphorylated inositol-requiring enzyme 1α (IRE1α) and X-box binding protein 1 (XBP1) splicing in HepG2 and 293T cells, thereby reducing endoplasmic reticulum stress.
  • Inquiry Price
Size
QTY
EC5026
BPN-19186
T111471809885-32-2In house
EC5026 (BPN-19186) has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.
  • Inquiry Price
Size
QTY
Dual FAAH/sEH-IN-1
T635362756099-59-7In house
Dual FAAH sEH-IN-1 is a dual inhibitor of sEH (soluble epoxide hydrolase) (IC50: 9.6 nM) and FAAH (fatty acid amide hydrolase) (IC50: 7 nM) with high affinity and anti-inflammatory activity.
  • Inquiry Price
10-14weeks
Size
QTY
TargetMol | Inhibitor Sale
(Rac)-EC5026
Urea, N-[3-fluoro-4-(trifluoromethoxy)phenyl]-N'-[1-(2-methyl-1-oxobutyl)-4-piperidinyl]-
T98321809885-55-9In house
(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) with a Ki of 0.06 nM, useful for research on Parkinson's disease and dementia with Lewy Bodies (DLB) [1].
  • Inquiry Price
7-10 days
Size
QTY
TargetMol | Inhibitor Sale
N,N'-Dicyclohexylurea
DCU, Dicyclohexylurea, Dicyclohexylcarbodiamide, NSC 17013, 1,3-Dicyclohexylurea
T230442387-23-7
N,N'-Dicyclohexylurea (AURORA KA-3582) is a soluble epoxide hydrolase (sEH) inhibitor.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
CUDA
T10900479413-68-8
CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases the activity of peroxisome proliferator-activated receptor (PPAR) alpha. CUDA may be valuable for the study of cardiovascular diseases.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
BI-1935
T14557940954-41-6
BI-1935 is an inhibitor of soluble epoxide hydrolase (sEH). For diseases related to cardiovascular disease.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
CAY10640
sEH inhibitor-1
T383671208549-68-1
CAY10640 (sEH inhibitor-1) is a potent, orally active, water-soluble epoxide hydrolase (sEH) inhibitor that inhibits sEH in humans and mice with IC50s of 0.4 and 5.3 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
sEH inhibitor-7
T60358340221-20-7
sEH inhibitor-7 is a soluble epoxide hydrolase (sEH) inhibitor that inhibits sEH in human and mouse with IC 50 s of 6.2 μM and 0.15 μM, respectively. sEH inhibitor-7 is associated with anti-inflammatory active molecules.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
AUDA
T7898479413-70-2
AUDA is an inhibitor of sEH(IC50 values of 18 and 69 nM for the mouse and human enzymes, respectively)
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Diflapolin
T8844724453-98-9
Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP) and soluble epoxide hydrolase (sEH) inhibitor, exhibiting marked anti-inflammatory efficacy and high target selectivity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
N-(3-methoxybenzyl)-octadecanamide
TN67941429659-99-3
N-(3-methoxybenzyl)-octadecanamide deverts from Maca (Lepidium meyenii Walp.).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SWE101
T130422376322-12-0
SWE101 is a potent human and rat soluble epoxide hydrolase (sEH)-P inhibitor(IC50s of 4 μM and 2.8 μM, respectively).
  • Inquiry Price
6-8 weeks
Size
QTY
AR-9281
APAU
T14315913548-29-5
AR-9281 (APAU) is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH) potentially for the treatment of hypertension and type 2 diabetes
  • Inquiry Price
Size
QTY
trans-AUCB
t-AUCB
T17158885012-33-9
trans-AUCB (t-AUCB) is an effective and selective soluble epoxide hydrolase inhibitor, with IC50 values of 1.3 nM for hsEH, 8 nM for mouse sEH, and 8 nM for rat sEH.
  • Inquiry Price
Size
QTY
UC-1728
t-TUCB
T17196948304-40-3
UC-1728 (t-TUCB) is an effective rabbit soluble epoxide hydrolase inhibitor (IC50: 2 nM on rabbit liver).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
DJ-53
T200655
DJ-53 (compound 68) is an orally active, phenyl-quinoline-based soluble epoxide hydrolase inhibitor.
  • Inquiry Price
Size
QTY
LQ-38
T200833
LQ-38 is an orally active, soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 5.2 nM. It has shown anti-inflammatory activity in rat foot edema models and in mouse models of acute pancreatitis, and exhibits analgesic effects in acetic acid-induced mouse writhing models.
  • Inquiry Price
Size
QTY
sEH inhibitor-19
T204461
sEH inhibitor-19 (Compound (R)-14i) is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 1.2 nM. This compound suppresses the expression of TNF-α and IL-6 and exhibits anti-inflammatory effects in mouse models of acute pancreatitis and Carrageenan-induced edema.
  • Inquiry Price
Size
QTY
sEH-IN-12
sEH inhibitor 12,sEH-inhibitor-12
T247781883803-09-5
sEH-IN-12 is an effective inhibitor of the enzyme soluble epoxide hydrolase (sEH).
  • Inquiry Price
6-8 weeks
Size
QTY
(±)12(13)-DiHOME
(±)12(13)-DiHOME, Isoleukotoxin diol
T35457263399-35-5
(±)12(13)-DiHOME is the diol form of (±)12(13)-EpOME , a cytochrome P450-derived epoxide of linoleic acid also known as isoleukotoxin. [1] It is formed from 12(13)-EpOME by soluble epoxide hydrolase (sEH) in neutrophils. [2] 12(13)-DiHOME is toxic to Sf21 cells expressing sEH and to lacZ-expressing control cells, unlike isoleukotoxin, which is only toxic to cells containing sEH.[1] [2] Levels of 12(13)-DiHOME are increased in rat spinal cord following burn injury, and it enhances cold tolerance, increases fatty acid uptake into brown adipocytes, and decreases serum triglyceride levels in mice. Levels are also elevated in bronchoalveolar lavage fluid (BALF) in humans following exposure to biodiesel exhaust and in exhaled breath condensate in patients with allergic asthma following allergen exposure.[5] [6] Plasma levels of 12(13)-DiHOME are increased immediately following moderate-intensity exercise in mice and humans, an effect that can be prevented by brown adipose tissue removal in the mouse.[7]
  • Inquiry Price
35 days
Size
QTY
(±)10(11)-EpDPA
T35493895127-65-8
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 10,11-double bond of DHA. It has been detected in rat brain and spinal cord, as well as human serum, and acts as a substrate for soluble epoxide hydrolase with a Km value of 5.1 μM. (±)10(11)-EpDPA and other epoxy metabolites of DHA are reported to demonstrate antihyperalgesic activity in inflammatory and neuropathic pain models and to potently inhibit angiogenesis and tumor growth in in vitro assays.
  • Inquiry Price
Size
QTY
(±)13(14)-EpDPA
T35496895127-64-7
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 13,14-double bond of DHA. It has been detected in rat brain and spinal cord and is a preferred substrate for soluble epoxide hydrolase with a Km value of 3.2 μM. (±)13(14)-EpDPA demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models. (±)13(14)-EpDPA and other epoxy metabolites of DHA are also reported to potently inhibit angiogenesis and tumor growth in in vitro assays.
  • Inquiry Price
Size
QTY